{[7,7-dimethyl-2-(methylsulfanyl)-6,9-dihydro-7H-pyrano[3',4':4,5]thieno[3,2-d]pyrimidin-4-yl]sulfanyl}acetic acid

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 噻吩并嘧啶酮衍生物
• 英文名称: {[7,7-dimethyl-2-(methylsulfanyl)-6,9-dihydro-7H-pyrano[3',4':4,5]thieno[3,2-d]pyrimidin-4-yl]sulfanyl}acetic acid
• 英文别名: 2-[(11,11-dimethyl-4-methylsulfanyl-12-oxa-8-thia-3,5-diazatricyclo[7.4.0.02,7]trideca-1(9),2(7),3,5-tetraen-6-yl)sulfanyl]acetic acid
• 化学式: C₁₄H₁₆N₂O₃S₃
• 分子量: 356.5
• InChiKey: GVXOVMYCAWNCPC-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.9
• 重原子数：
  22
• 可旋转键数：
  4
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  151
• 氢给体数：
  1
• 氢受体数：
  8

文献信息

• SMALL MOLECULE BICYCLIC AND TRICYCLIC CFTR CORRECTORS
  申请人：DISCOVERYBIOMED, INC.

  公开号：US20150307503A1

  公开（公告）日：2015-10-29

  Novel CFTR corrector compounds that are effective in rescuing halide efflux, delF508-CFTR protein processing, and apical functional chloride ion transport in a cell are provided. Also provided are methods for treating protein folding disorders (e.g., cystic fibrosis). The methods include administering a CFTR corrector compound or pharmaceutically acceptable salt or prodrug thereof. Methods of rescuing halide efflux in a cell, correcting a processing defect of a delF508-CFTR protein in a cell, and correcting functional delF508-CFTR chloride channels in a cell are also provided.

  提供了一种在细胞中有效拯救卤化物流出、修复delF508-CFTR蛋白加工和顶端功能氯离子传输的新型CFTR校正化合物。还提供了治疗蛋白质折叠障碍（例如囊性纤维化）的方法。该方法包括给予CFTR校正化合物或其药用可接受的盐或前药。还提供了在细胞中拯救卤化物流出、纠正细胞中delF508-CFTR蛋白的加工缺陷以及纠正细胞中功能性delF508-CFTR氯通道的方法。
• US9546176B2
  申请人：——

  公开号：US9546176B2

  公开（公告）日：2017-01-17
• [EN] Small Molecule Bicyclic and Tricyclic CFTR Correctors<br/>[FR] CORRECTEURS DE CFTR BICYCLIQUES ET TRICYCLIQUES À PETITES MOLÉCULES
  申请人：DISCOVERYBIOMED INC

  公开号：WO2014081821A2

  公开（公告）日：2014-05-30

  Novel CFTR corrector compounds that are effective in rescuing halide efflux, delF508-CFTR protein processing, and apical functional chloride ion transport in a cell are provided. Also provided are methods for treating protein folding disorders (e.g., cystic fibrosis). The methods include administering a CFTR corrector compound or pharmaceutically acceptable salt or prodrug thereof. Methods of rescuing halide efflux in a cell, correcting a processing defect of a delF508-CFTR protein in a cell, and correcting functional delF508-CFTR chloride channels in a cell are also provided.